AWM
PCRX icon

Abound Wealth Management’s Pacira BioSciences PCRX Stock Holding History

Abound Wealth Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10
Closed -$151 – 1320
2024
Q3 		$151 Hold
10
– – ﹤0.01% 1260
2024
Q2 		$287 Hold
10
– – ﹤0.01% 996
2024
Q1 		$293 Hold
10
– – ﹤0.01% 1144
2023
Q4 		$338 Buy
10
+4
+67% +$117 ﹤0.01% 1108
2023
Q3 		$185 Hold
6
– – ﹤0.01% 1118
2023
Q2 		$241 Buy
+6
New +$248 ﹤0.01% 1119

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Abound Wealth Management's PCRX Position: Q4 2024 in Review

Abound Wealth Management sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 10 shares — an estimated $151 sold.

Abound Wealth Management first reported a position in PCRX in Q2 2023 and held it in 6 quarters. The position peaked at $338 in Q4 2023. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

  • Abound Wealth Management reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
  • Abound Wealth Management sold 10 Pacira BioSciences shares in Q4 2024, an estimated $151.
  • Abound Wealth Management first reported a position in Pacira BioSciences in Q2 2023 and held it in 6 quarters.
  • Abound Wealth Management's Pacira BioSciences position peaked at $338 in Q4 2023.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Abound Wealth Management's 13F filing for Q4 2024, filed 13 Jan 2025.